Restrictive Pulmonary Diseases

Restrictive Pulmonary Diseases Overview

Restrictive pulmonary diseases are characterized by difficulty in lung expansion, leading to challenges in getting air into the lungs while not impacting the ability to exhale. Various factors contribute to this condition, including fibrotic changes and lung scarring. Two critical examples of restrictive pulmonary diseases are sarcoidosis and idiopathic pulmonary fibrosis (IPF). Additionally, pneumoconioses represent a category of such diseases associated with occupational inhalation of various dusts and minerals.

Sarcoidosis

Sarcoidosis is an idiopathic, multi-system inflammatory disease marked by the formation of non-caseating granulomas, primarily in the lungs and intrathoracic lymph nodes. The pathology involves an exaggerated T-cell response, causing excessive immune reactions, inflammation, and granuloma formation throughout the body.

Risk Factors

In clinical vignettes, look for the presence of an African-American female, as this demographic is at a higher risk of sarcoidosis, being three to four times more likely to be affected than other races, with a slight female predominance.

Clinical Manifestations

Patients may be asymptomatic, with many cases discovered incidentally during routine chest radiographs. Common pulmonary symptoms include:

  • Non-productive cough
  • Dyspnea on exertion
  • Chest pain
    More specific manifestations include:
  • Erythema nodosum: Painful nodules on the lower extremities, which can indicate Lofgren syndrome when associated with migratory arthralgias and bilateral hilar lymphadenopathy.
  • Lupus pernio: Pathognomonic violaceous plaques on the face, particularly affecting the nose and cheeks, commonly observed in African-American patients.
  • Bilateral hilar lymphadenopathy: This is the classic finding, appearing as enlarged lymph nodes on chest X-rays.
  • Restrictive cardiomyopathy: Due to granuloma deposition in the myocardium.
Diagnosis

Sarcoidosis lacks a definitive test, but diagnosis typically involves:

  1. Aligning clinical manifestations with radiographic findings.
  2. Excluding similar diseases (like tuberculosis).
  3. Detecting non-caseating granulomas in biopsy samples, which can be taken from various affected tissues.
  4. A notable increase in serum ACE levels (although this test has poor sensitivity).
Treatment

The primary treatment for sarcoidosis focuses on corticosteroids, with oral steroids being the first-line therapy. Many patients may experience spontaneous remission, while others could require medication for symptom relief.

Remembering Key Points

To recall important aspects of sarcoidosis, use the acronym "ACE LSH":

  • A: African-American predisposition
  • C: Cough (dry)
  • E: Erythema nodosum
  • L: Lupus pernio
  • S: Steroids (treatment)
  • H: Hilar lymphadenopathy

Idiopathic Pulmonary Fibrosis (IPF)

IPF is a rare lung disease characterized by progressive scarring of lung tissue with no known etiology.

Risk Factors

Risk factors differ from those in sarcoidosis, including:

  • Cigarette smoking: The majority of patients have a smoking history.
  • Age: Typically affects older adults, especially those in their sixties and seventies, being rare in individuals under fifty.
  • Gender: More common in males than females.
Clinical Manifestations

Symptoms often include:

  • Dyspnea on exertion and non-productive cough, which usually develop gradually over several months.
  • Physical examination may reveal bibasilar crackles and possible finger clubbing.
Diagnosis

Similar to sarcoidosis, diagnosis involves a pulmonary function test revealing a restrictive pattern (normal or increased FEV1/FVC ratio). A CT scan is essential, showing findings such as:

  • Honeycombing: Peripheral cyst-like structures indicating advanced fibrosis.
  • Traction bronchiectasis: Abnormally dilated bronchi due to fibrotic damage.
  • Bilateral ground-glass opacities: Hazy opacities resulting from scarring.
Treatment

Treatment options for IPF are limited, primarily focusing on supportive care. Most patients will eventually need supplemental oxygen therapy. The only medications shown to slow disease progression are pirfenidone and nintedanib, as lung transplant remains the definitive option for severe cases.

Pneumoconioses

Pneumoconioses are a subset of interstitial lung diseases resulting from inhaled mineral dusts and are generally linked to occupational exposures.

Key Types:
  1. Coal Workers' Pneumoconiosis: Associated with inhaling coal dust; nodules typically reside in the upper lobes due to deep work environments. Kaplan syndrome, characterized by the combination of this condition and rheumatoid arthritis, may also be relevant.
  2. Byssinosis: Related to cotton dust exposure in the textile industry, leading to conditions often impacting workers in these factories.
  3. Asbestosis: Caused by asbestos exposure, resulting in lung fibrosis, often found in individuals renovating buildings or working with insulation. Fibrotic changes may show a "shaggy heart sign" on X-ray, indicating indistinct heart borders due to interstitial involvement.
  4. Berylliosis: Chronic lung disease from beryllium exposure, commonly linked to aerospace and electronics industries.
  5. Silicosis: Driven by silica exposure (granite, sandblasting), particularly affecting individuals working in mining or masonry, known for its eggshell calcifications seen on imaging.